Wells Fargo raised the firm’s price target on Insmed (INSM) to $217 from $171 and keeps an Overweight rating on the shares. The firm thinks the stock move on Thursday is largely on greater optimism for NCFBE. But while management commentary focused on PE=2+, Wells’ initial key opening leader feedback suggests physician appetite to reconsider borderline PE=1 patients, suggesting upside to the TAM.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed’s Q3 2025 Earnings Highlight Growth and Expansion
- Strong Financial Performance and Promising Pipeline Drive Buy Rating for Insmed
- Insmed’s Strong Financial Performance and Promising Product Launches Reinforce Buy Rating
- Insmed raises 2025 global Arikayce revenue view to $420M-$430M from $405M-$425M
- Insmed reports Q3 EPS ($1.75), consensus ($1.37)